Author-year | Design | Study population | Intervention | Total, n | Age, median (IQR), year | Male, % | BMI, median (IQR), kg/m2 |
---|---|---|---|---|---|---|---|
Spyropoulos-2021 [21] | multicenter, active control randomized clinical trial | Hospitalized with COVID-19 (noncritically and critically ill) | Therapeutic (TA): enoxaparin (1 mg/kg BID or 0.5 mg/kg BID) | 129 | 65.8 ± 13.9a | 52.7 | 31.2 ± 9.3a |
Standard (PA): LMWH (Up to 22,500 IU BID or TID) or enoxaparin (30 mg or 40 mg QD or BID).et | 124 | 67.7 ± 14.1a | 54.8 | 29.8 ± 13.6a | |||
Lemos-2020 [13] | open-label RCT single-center, phase II | Hospitalized with COVID-19 (and ARDS) | Therapeutic (TA): enoxaparin (1 mg/kg BID or 0.75 mg/kg BID or 1 mg/kg QD) | 10 | 55 ± 10a | 90 | 33 ± 8a |
Prophylactic (PA): enoxaparin (40 mg QD or 40 mg BID) or UFH (5000 IU TID or 7500 IU TID) | 10 | 58 ± 16a | 70 | 34 ± 8a | |||
Goligher-2021 [12] | open-label RCT adaptive, multiplatform | Hospitalized with severe COVID-19(critically ill) | Therapeutic (TA): UFH or LMWH | 536 | 60.4 ± 13.1a | 72.2 | 30.4 (26.9–36.1) |
Usual-Care (PA): local standard venous thromboprophylaxis | 567 | 61.7 ± 12.5a | 67.9 | 30.2 (26.4–34.9) | |||
Lawler-2021 [22] | open-label RCT adaptive, multiplatform | Hospitalized with COVID-19(noncritically ill) | Therapeutic (TA): UFH or LMWH | 1181 | 59.0 ± 14.1a | 60.4 | 29.8 (26.3–34.7) |
Usual-Care (PA): local standard venous thromboprophylaxis | 1050 | 58.8 ± 13.9a | 56.9 | 30.3 (26.7–34.9) | |||
Connors-2021 [26] | adaptive, randomized, double-blind, placebo-controlled trial | Hospitalized with COVID-19 (symptomatic but clinically stable outpatients) | Therapeutic (TA): apixaban (5 mg BID) | 164 | 52 (47–58) | 37.8 | 31.1 (26.2–35.4) |
Prophylactic (PA): apixaban (2.5 mg BID) | 165 | 55 (46–61) | 42.4 | 29.9 (26.2–34.8) | |||
Marcos-Jubilar-2021 [23] | open-label, multicenter RCT | Hospitalized with COVID-19 (noncritically ill) | Therapeutic (TA): bemiparin (115 IU/kg QD) | 32 | 62.3 ± 12.2a | 53.1 | 25.8 (24.0–29.4) |
Standard (PA): bemiparin (3500 IU QD) | 33 | 63.0 ± 13.7a | 72.7 | 26.1 (24.1–28.8) | |||
Sholzberg-2021 [24] | Randomized controlled, adaptive, open label clinical trial. | Hospitalized with COVID-19(and elevated d-dimer) | Therapeutic (TA): UFH or LMWH | 228 | 60.4 ± 14.1a | 53.9 | 30.3 ± 6.4a |
Prophylactic (PA): UFH or LMWH | 237 | 59.6 ± 15.5a | 59.5 | 30.2 ± 7.0a | |||
Morici-2021 [25] | open-label, multicenter, controlled, randomized trial | Hospitalized with COVID-19 (noncritically ill) | Therapeutic (TA): enoxaparin (40 mg BID) | 91 | 60 (53–73) | 61.5 | 26 (24–28) |
Prophylactic (PA): enoxaparin (40 mg QD) | 92 | 59 (48–72) | 64.1 | 25 (23–28) | |||
Sadeghipour-2021 [27] | Multicenter randomized trial | Admitted to ICU with COVID-19 | Intermediate (TA): enoxaparin (1 mg/kg QD) | 276 | 62(51–70.7) | 58.7 | 26.7 (24.4–29.1) |
Standard (PA): enoxaparin (40 mg QD) | 286 | 61(47–71) | 57 | 27.2 (24.3–29.1) | |||
Lopes-2021 [14] | open-label RCT pragmatic | Hospitalized with COVID-19 (stable and unstable) | Therapeutic (TA): rivaroxaban (20 mg or 15 mg QD) | 311 | 56.7 ± 14.1a | 62 | 30.3 ± 6.0a |
Prophylactic (PA): standard in-hospital enoxaparin or UFH | 304 | 56.5 ± 14.5a | 58 | 30.3 ± 6.1a | |||
Perepu-2021 [11] | open-label RCT multi-center | Hospitalized with COVID-19 (ICU and/or coagulopathy) | Intermediate (TA): enoxaparin (40 mg QD or 30 mg BID or 40 mg BID) | 87 | 65 (24–86) | 54 | 30.0 (24.7–36.6) |
Standard (PA): enoxaparin (1 mg/kg QD) or0.5 mg/kg BID | 86 | 63.5 (30–85) | 58 | 30.7 (27.2–35.8) |